Perspective - Journal of Diabetes Medication & Care (2025) Volume 8, Issue 2
Injectable Diabetes Therapies: Expanding Options for Effective Glycemic Control
Dr. Ahmed El-Sayed*
Dept. of Internal Medicine, Nile Delta University, Egypt
- *Corresponding Author:
- Dr. Ahmed El-Sayed
Dept. of Internal Medicine, Nile Delta University, Egypt
E-mail: ahmed.elsayed@ndu.eg
Received: 01-Apr-2025, Manuscript No. jdmc-26-184883; Editor assigned: 03- Apr -2025, PreQC No. jdmc-26-184883 (PQ); Reviewed: 18- Apr -2025, QC No. jdmc-26-184883; Revised: 21- Apr -2025, Manuscript No. jdmc-26-184883 (R); Published: 30- Apr -2025, DOI: 10.37532/JDMC.2025.7(2). 285
Introduction
Injectable therapies play a central role in the management of diabetes, particularly for individuals who require treatment beyond oral medications. While insulin has long been the foundation of injectable therapy, the therapeutic landscape has expanded significantly with the development of non-insulin injectable agents. These therapies provide diverse mechanisms of action, enabling more individualized treatment strategies. Injectable diabetes treatments are designed not only to control blood glucose levels but also to address weight management, cardiovascular risk, and long-term metabolic health [1,2].
Discussion
Insulin remains the most established injectable therapy for both type 1 diabetes and advanced type 2 diabetes. Modern insulin formulations include rapid-acting, long-acting, and ultra-long-acting analogs that more closely mimic physiological insulin secretion. Advances in pen devices and continuous subcutaneous insulin infusion systems have improved dosing accuracy, flexibility, and patient convenience [3,4]. These innovations have reduced hypoglycemia risk and enhanced quality of life.
Beyond insulin, glucagon-like peptide-1 (GLP-1) receptor agonists have become a cornerstone of injectable therapy in type 2 diabetes. These agents stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety. As a result, they effectively lower blood glucose while supporting weight loss and offering cardiovascular protection in high-risk patients. Once-daily and once-weekly formulations have improved adherence and broadened their clinical use [5].
Combination injectable therapies have also emerged, integrating basal insulin with GLP-1 receptor agonists in a single device. These fixed-ratio combinations simplify regimens, enhance glycemic control, and reduce the risk of weight gain and hypoglycemia compared with insulin alone. Such therapies are particularly useful for patients who require intensification of treatment but prefer fewer injections.
Patient education and shared decision-making are critical components of successful injectable therapy. Proper injection technique, site rotation, and understanding of dosing schedules help prevent complications and improve outcomes. Technological advancements, including smart pens and glucose-linked insulin delivery systems, further enhance safety and personalization.
Conclusion
Injectable diabetes therapies have evolved far beyond traditional insulin injections, offering a broad array of options tailored to individual patient needs. With improved formulations, combination products, and advanced delivery systems, injectable treatments now address multiple aspects of metabolic health. As innovation continues, these therapies will remain essential in achieving optimal glycemic control, reducing complications, and improving quality of life for people living with diabetes.
References
- Nikfar R, Shamsizadeh A, Darbor M, Khaghani S, Moghaddam M. (2017) A Study of prevalence of Shigella species and antimicrobial resistance patterns in paediatric medical center, Ahvaz, Iran. Iran J Microbiol 9: 277.
- Kacmaz B, Unaldi O, Sultan N, Durmaz R (2014) Drug resistance profiles and clonality of sporadic Shigella sonnei isolates in Ankara, Turkey. Braz J Microbiol 45: 845â849.
- Akcali A, Levent B, AkbaÅ E, Esen B (2008) Typing of Shigella sonnei strains isolated in some provinces of Turkey using antimicrobial resistance and pulsed field gel electrophoresis methods. Mikrobiyol Bul 42: 563â572.
- Jafari F, Hamidian M, Rezadehbashi M, Doyle M, Salmanzadeh-Ahrabi S, et al. (2009) Prevalence and antimicrobial resistance of diarrheagenic Escherichia coli and Shigella species associated with acute diarrhea in Tehran, Iran. Can J Infect Dis Med Microbiol 20: 56â62.
- Ranjbar R, Behnood V, Memariani H, Najafi A, Moghbeli M, et al. (2016) Molecular characterisation of quinolone-resistant Shigella strains isolated in Tehran, Iran. J Glob Antimicrob Resist 5: 26â30.
